Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Patent
1995-10-23
1998-06-16
Azpuru, Carlos
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
424435, 5147723, 5147726, 514774, 514777, 514781, A61F 902, A61K 4730, A61K 4732, A01N 2534
Patent
active
057666202
ABSTRACT:
Drug delivery systems and methods for administering a glucagon-like insulinotropic peptide to the buccal mucosa for transmucosal drug delivery are described. The drug delivery systems comprise a drug composition containing an effective amount of the glucagon-like insulinotropic peptide and an effective amount of a permeation enhancer for enhancing permeation of glucagon-like insulinotropic peptide through the buccal mucosa and means for maintaining the drug composition in a drug transferring relationship with with buccal mucosa. These systems can be in free form, such as creams, gels, and ointments, or can comprise a device of determined physical form, such as tablets, patches, and troches. A preferred glucagon-like insulinotropic peptide is GLP-1(7-36)amide.
REFERENCES:
patent: 5118666 (1992-06-01), Habener
patent: 5120712 (1992-06-01), Habener
patent: 5346701 (1994-09-01), Heiber et al.
patent: 5552520 (1996-09-01), Kim et al.
patent: 5614492 (1997-03-01), Habener
G.I. Bell, et al., Exon Duplication and Divergence in the Human Preproglucagon Gene, 304 Nature 368-371 (1983).
M. Gutniak, et al., Antidiabetogenic Effect of Glucagon-Like Peptide-1 (7-36) Amide in Normal Subjects and Patients with Diabetes Mellitus, The New England Journal of Medicine, 1316-1322 (1992).
M.A. Nauck, et al., Preserved Incretin Activity of Glucagon-like Peptide 1 Patients with Type-2 Diabetes Mellitus, 91 The American Society for Clinical Investigation, Inc. 301-307 (1993).
M.A. Nauck, et al., Additive Insulinotropic Effects of Exogenous Synthetic Human Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1-7(7-36) Amide Infused at Near-Physiological Insulinotropic Hormone and Glucose Concentrations, 76 Journal of Clinical Endocrinology and Metabolism 912-917 (1993).
C. .O slashed.rskov, et al., Proglucagon Products in Plasma of Noninsulin-dependent Diabetics and Nondiabetic Controls in the Fasting State and after Oral Glucose and Intravenous Arginine, 87 The American Society for Clinical Investigation, Inc., 415-423 (1991).
J.E. Gerich, Oral Hypoglycemic Agents, 321 New England Journal of Medicine 1231-1245.
M. Gutniak, et al., Glyburide Decreases Insulin Requirement, Increases .beta.-cell Response to Mixed Meal, and Does Not Affect Insulin Sensitivity: Effects of Short- and Long-Term Combined Treatment in Secondary Failure to Sulfonylurea. 10 Diabetes Care 545-553 (1987).
H.E. Lebovitz and M.N. Feinglos, Sulfonylurea Drugs: Mechanism of Antidiabetic Action and Therapeutic Usefulness. 1 Diabetes Care 189-198 (1978).
C. .O slashed.rskov, et al., Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and Glucagonlike Peptide-1 7-37 in Healthy Subjects Are Indistinguishable, 42 Diabetes, 658-661 (1993).
D. Gefel, et al., Glucagon-Like Peptide-I Analogs: Effects on Insulin Secretion and Adenosine 3',5'-Monophosphate Formation, 126 Endocrinology, 2164-2168 (1990).
Some Aspects of Human Biochemistry, Chapter 25 (Hormones), pp. 735-741.
D.M. Nathan, et al., Insulinotropic Action of Glucagonlike Peptide-1-(7-37) in Diabetic and Nondiabetic Subjects, 15 Diabetes Care 270-276 (1992).
D. Harris and J. R. Robinson, Bioadhesive polymers in peptide drug delivery, Biomaterials 1990.
M.E. de Vries et al., Developments in Buccal Drug Delivery, 8 Critical Reviews in Therapeutic Drug Carrier Systems, 271-303 (1991).
D. Harris and J.R. Robinson, Drug Delivery via the Mucous Membranes of the Oral Cavity, 81 Journal of Pharmaceutical Sciences 1-10 (1992).
M.E. de Vries, et al. Hydrogels for Buccal Drug Delivery: Properties Relevant for Muco-adhesion, 22 Journal of Biomedical Materials Research 1023-1032 (1988).
M.K. Gutniak, et al. Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM, 17 Diabetes Care (1994).
M.A. Nauck et al., Normalization of Fasting Hyperglycaemia by Exogenous Glucagon-Like Peptide 1 (7-36 amide) in Type 2 (non-insulin dependent) Diabetic Patients, Diabetologia (1993).
Stephanie A. Amiel, Glucagon-Like Peptide: A Therapeutic Glimmer, 343 Lancet (Jan. 1, 1994).
M.K. Gutniak et al., GLIP (Glucagon-Like Insulinotropic Peptide) Has A Stronger Antidiabetogenic Effect Than Glibenclamide 36 Diabetologia (1993)(abstract).
I. Valverde et al., Glucagon-Like Peptide 1 (7-36) Amide: A Potent Glycongenic Hormone, 36 Diabetologia (1993)(abstract).
E. Delgado, et al. Identification and Characterization of GLP-1(7-36) Amide Receptors in Rat Skeletal Muscle, 36 Diabetologia (1993)(abstract).
M.L. Villanueva-Penacarrillo et al., Presence and Characterization of GLP-1(7-36) Amide Receptors in the Rat Liver, 36 Diabetologia (1993)(abstract).
H. Kofod, et al. Glucagon Acts on .beta.-Cells By Cross Reaction With The GLP-1(7-36) Amide Receptor, 36 Diabetologia (1993)(abstract).
J.L. Gromada, et al. Induction of Glucose Responsiveness in Pancreatic .beta.-Cells By Glucagon-Like Peptide 1. 36 Diabetologia (1993)(abstract).
S. Efendic, et al. Subcutaneous Injection of Glucagon-Like Insulinotropic Peptide Reduces Postprandial Glycemia in Type 2 Diabetes, 36 Diabetologia (1993)(abstract).
M.A. Nauck, et al. Insulinotropic Actions of GIP and GLP-1 (7-36 Amide), But Not of CCK-8 at Physiologically Elevated Amino Acid Concentrations, 36 Diabetologia (1993)(abstract).
E. Heinze, et al. Reduced GIP Contributes to Altered Insulin Response Following Oral Glucose in Women with Turner Syndrome, 36 Diabetologia (1993)(abstract).
Ebert Charles D.
Gutniak Mark K.
Heiber Sonia J.
Azpuru Carlos
TheraTech Inc.
LandOfFree
Buccal delivery of glucagon-like insulinotropic peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Buccal delivery of glucagon-like insulinotropic peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Buccal delivery of glucagon-like insulinotropic peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1722128